Emer­gent to de­liv­er a $120M con­tract for the small­pox vac­cine for the US stock­pile

Emer­gent BioSo­lu­tions, a vac­cine and ther­a­peu­tic man­u­fac­tur­er for de­fense pur­pos­es, is ce­ment­ing its small­pox vac­cine pro­duc­tion sta­tus by ink­ing a con­tract with the US gov­ern­ment.

On Tues­day, Emer­gent an­nounced that it has a con­tract to de­liv­er the ACAM200 small­pox vac­cine to the Strate­gic Na­tion­al Stock­pile. Emer­gent said in a re­lease that this op­tion is the third of nine an­nu­al con­tract ex­ten­sions, with this ex­ten­sion be­ing worth around $120 mil­lion. The con­tract is al­so a part of Emer­gent’s 10-year, $2 bil­lion deal with HHS’s Of­fice of the As­sis­tant Sec­re­tary for Pre­pared­ness and Re­sponse set up in 2019.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER